Masaharu Takamori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masaharu Takamori has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Hiroaki Yoshikawa
Affiliation Health Service Center, Kanazawa University, Kanazawa, Ishikawa, Japan
2 shared publications M. Motomura
First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
2 shared publicationsK. Otsuka
From the Neurological Center (Drs. Takamori and Otsuka), Kanazawa-Nishi Hospital, Kanazawa; Department of Internal Medicine (Dr. Motomura), Nagasaki University Hospital; Department of Neurology (Drs. Kawaguchi, Nemoto, and Hattori), Chiba University Hospital; and Department of Neurology (Dr. Yoshikawa), Kanazawa University Hospital, Japan
1 shared publicationN. Kawaguchi
From the Neurological Center (Drs. Takamori and Otsuka), Kanazawa-Nishi Hospital, Kanazawa; Department of Internal Medicine (Dr. Motomura), Nagasaki University Hospital; Department of Neurology (Drs. Kawaguchi, Nemoto, and Hattori), Chiba University Hospital; and Department of Neurology (Dr. Yoshikawa), Kanazawa University Hospital, Japan
1 shared publicationT. Fukudome
Department of Clinical Research, Nagasaki Medical Center of Neurology, Kawatana, Japan
1 shared publicationT. Hattori
From the Neurological Center (Drs. Takamori and Otsuka), Kanazawa-Nishi Hospital, Kanazawa; Department of Internal Medicine (Dr. Motomura), Nagasaki University Hospital; Department of Neurology (Drs. Kawaguchi, Nemoto, and Hattori), Chiba University Hospital; and Department of Neurology (Dr. Yoshikawa), Kanazawa University Hospital, Japan
1 shared publication
Latest Publications
- 1 August 2008
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 200 (1-2) , 142-144
Autoantibodies against TRPC3 and ryanodine receptor in myasthenia gravis
- 1 August 2008
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 200 (1-2) , 142-144
Autoantibodies against TRPC3 and ryanodine receptor in myasthenia gravis
- 25 July 2008
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 201, 145-152
Lambert–Eaton myasthenic syndrome: Search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis
- 25 July 2008
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 201, 145-152
Lambert–Eaton myasthenic syndrome: Search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis
- 19 October 2007
- Published by Wiley in European Journal of Neurology
- Vol. 14 (11) , 1230-1235
Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders
The Lambert–Eaton myasthenic syndrome (LEMS), often associated with small‐cell lung carcinoma (SCLC), is a disorder of acetylcholine (ACh) release from motor nerve terminals. In most patients, it is caused by autoantibodies against the P/Q‐type voltage‐gated calcium channels (VGCC) that trigger ACh release. However, these antibodies are not detected in approximately 15% of clinically and electrophysiologically typical cases. The M1‐type pre‐synaptic muscarinic ACh receptor (M1 mAChR) modulates cholinergic neuromuscular transmission by linking to P/Q‐type VGCC, and may partially compensate for the reduced calcium entry. Immunoblotting against solubilized human M1 mAChR, we detected autoantibodies in: (a) 14 of 20 (70%) anti‐VGCC‐positive LEMS patients; (b) all five anti‐VGCC‐negative LEMS patients, one of whose serum had previously passively transferred LEMS‐type electrophysiological defects to mice; (c) all five LEMS patients with autonomic symptoms; (d) seven of 25 (28%) myasthenia gravis (MG) patients in whom increased ACh release partially compensates for post‐synaptic defects; (e) none of 10 SCLC patients without LEMS. Although not proving primary pathogenicity of anti‐M1 mAChR antibodies, the present results highlight their potential to affect synaptic compensatory mechanisms, more in LEMS than MG.
- 19 October 2007
- Published by Wiley in European Journal of Neurology
- Vol. 14 (11) , 1230-1235
Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders
The Lambert–Eaton myasthenic syndrome (LEMS), often associated with small‐cell lung carcinoma (SCLC), is a disorder of acetylcholine (ACh) release from motor nerve terminals. In most patients, it is caused by autoantibodies against the P/Q‐type voltage‐gated calcium channels (VGCC) that trigger ACh release. However, these antibodies are not detected in approximately 15% of clinically and electrophysiologically typical cases. The M1‐type pre‐synaptic muscarinic ACh receptor (M1 mAChR) modulates cholinergic neuromuscular transmission by linking to P/Q‐type VGCC, and may partially compensate for the reduced calcium entry. Immunoblotting against solubilized human M1 mAChR, we detected autoantibodies in: (a) 14 of 20 (70%) anti‐VGCC‐positive LEMS patients; (b) all five anti‐VGCC‐negative LEMS patients, one of whose serum had previously passively transferred LEMS‐type electrophysiological defects to mice; (c) all five LEMS patients with autonomic symptoms; (d) seven of 25 (28%) myasthenia gravis (MG) patients in whom increased ACh release partially compensates for post‐synaptic defects; (e) none of 10 SCLC patients without LEMS. Although not proving primary pathogenicity of anti‐M1 mAChR antibodies, the present results highlight their potential to affect synaptic compensatory mechanisms, more in LEMS than MG.
- 1 October 2004
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 322 (4) , 1347-1351
Lambert–Eaton myasthenic syndrome as an autoimmune calcium channelopathy
- 1 October 2004
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 322 (4) , 1347-1351
Lambert–Eaton myasthenic syndrome as an autoimmune calcium channelopathy
- 25 May 2004
- Published by Wolters Kluwer Health in Neurology
- Vol. 62 (10) , 1894-1896
Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis
Anti-ryanodine receptor (RyR) antibodies were measured in sera from 33 myasthenia gravis (MG) patients using three peptides from the human RyR1 sequence, two C-terminal peptides included in the functional calcium release channel, and an N-terminal peptide implicated in ion-conduction. Antibodies were more frequently positive against the two C-terminal peptides, particularly in thymoma-associated MG. In a preliminary open trial with FK506, immunosuppressant and enhancer of RyR-related sarcoplasmic calcium release, the authors observed the sustained benefits in anti-RyR-positive MG patients.
- 25 May 2004
- Published by Wolters Kluwer Health in Neurology
- Vol. 62 (10) , 1894-1896
Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis
Anti-ryanodine receptor (RyR) antibodies were measured in sera from 33 myasthenia gravis (MG) patients using three peptides from the human RyR1 sequence, two C-terminal peptides included in the functional calcium release channel, and an N-terminal peptide implicated in ion-conduction. Antibodies were more frequently positive against the two C-terminal peptides, particularly in thymoma-associated MG. In a preliminary open trial with FK506, immunosuppressant and enhancer of RyR-related sarcoplasmic calcium release, the authors observed the sustained benefits in anti-RyR-positive MG patients.